ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug
PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences ...
PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences ...
© 2024 All Rights Reserved: STOXPO.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information
Do you really wish to opt-out?